Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing drugs for chronic renal and inflammatory diseases. Its platforms include VAR 200, targeting kidney disorders like FSGS and diabetic kidney disease, and IC 100, a monoclonal antibody for inflammatory conditions such as obesity, MS, and neurodegenerative diseases. The company focuses on indication expansion, proprietary technologies, and strategic licensing to address high unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.